Help us get life-saving drug approved for covid-19

Please watch VIDEO at https://tinyurl.com/hcvbduxp 

The search for a treatment for Covid-19

What is ivermectin? Please see the evidence. Visit www.e-bmc.co.uk and www.thebird-group.org and www.covid19criticalcare.com  and www.ivmmeta.com 

In countries across the globe, deaths from covid-19 have now exceeded 2.4 million people. To date, very few treatments have been identified by the health authorities to reduce hospitalisations and deaths linked to covid-19. However, many doctors around the world are using a medicine called ivermectin to treat covid-19 patients. In the past year, the list of countries that use ivermectin for the prevention and treatment of covid has grown to include 25% of the world;  Czech Republic, USA (off-label),  Argentina, Belize, Brazil (some provinces), Slovenia, Bolivia, Honduras, Bulgaria, Dominican Republic, El Salvador, Egypt,  Guatemala, Honduras, Lebanon, Mexico (some regions), Nicaragua, Nigeria (many regions), North Macedonia (mixed usage), Panama,  India, Peru, Slovakia, South Africa, Venezuela and Zimbabwe. Based on the latest evidence, doctors and scientists are calling for ivermectin's approval in every country of the world.

What is ivermectin?

Ivermectin is a medication that has been widely used for around forty years to treat parasitic infections in adults and children. It is considered safe and effective and is notable for its antiviral and anti-inflammatory properties. More than 3½ billion doses of ivermectin have been given worldwide. It is included in the World Health Organization’s Model List of Essential Medicines and in 2015 its discoverers won a Nobel Prize in Medicine.

Dr Tess Lawrie is a medical doctor and researcher based in Bath, UK, who runs the Evidence-Based Medicine Consultancy (E-BMC). She first became interested in the ivermectin story when, in December 2020, she saw Dr Pierre Kory asking the US State Senate to allow doctors to prescribe ivermectin for use against covid-19. After going through the studies that Dr. Kory referenced and writing a preliminary report of her findings, Dr Lawrie and her team of experienced researchers reviewed and assessed the evidence on ivermectin for covid-19 and shared it widely in the UK and internationally.

55358286_1615982222466002_r.jpeg
Ivermectin could turn the tide 

The evidence from the review team showed that people with covid-19 who were treated with ivermectin were approximately 68% less likely to die than people who didn’t receive ivermectin. In practical terms this means that, in a hospital where nine people out of a hundred die from covid, ivermectin could reduce this number to three per 100. The review also shows that covid symptoms were less likely to worsen if a person received ivermectin.

They also found evidence on the use of ivermectin for prevention of covid-19 among people at high risk of infection, such as health care workers and covid-19 contacts. This showed that ivermectin may prevent 4 out of every 5 covid-19 infections among these high-risk groups. 

55358286_1615982247293128_r.jpeg
What are we doing about it?

In February 2021, Dr. Lawrie presented the evidence to a panel of covid experts, health professionals, and the patient representatives at the British Ivermectin Recommendation Development (BIRD) meeting. After hearing the evidence, the BIRD panel recommended that ivermectin be implemented immediately for the prevention and treatment of covid-19. 

Dr Lawrie’s team has urgently shared this recommendation from the BIRD meeting with the relevant UK policy and decision makers (PHE, NICE, MHRA), regulatory bodies and implementers. The team has also sent the documents to influential health organisations including the World Health Organization (WHO) the United States National Institutes of Health (NIH), the Food and Drug Administration and others. 

55358286_1615982267176280_r.jpeg
Why do we need your help?

So far, ivermectin remains unlicensed for the prevention and treatment of covid-19 in the UK and many other countries around the world. Therefore, Dr. Lawrie and her team need to do further work to educate health professionals and politicians as quickly as possible to avoid further unnecessary loss of life and improve health outcomes for covid survivors.

We need your help to continue our work to get ivermectin approved in the UK and worldwide. 

Your donations will go towards the following expenses over the next three months:

- E-BMC running costs:  currently two staff working full-time and one part-time on ivermectin research and education.
- Public education and awareness raising through the BIRD initiative, e.g. creating a website, responding to queries, interviews, press outreach, government lobbying.
- Expert opinion fees: e.g. statistician, regulatory authorities consultants, legal, clinical trial experts.
- Planning proposal for a trial of ivermectin to treat long-covid
- Planning further covid-19 related public health research
- To establish E-BMC Ltd. as a non-profit community interest company (CIC). This process will involve engaging a business consultant to help us convert our financial model to a non-profit model.  We aim to expand our team to respond more effectively to the urgent public health and research needs during this pandemic.
- Other expenses, e.g. MHRA application costs if necessary

Thank you kindly for your support.
  • Anna Fortes Mayer 
    • £10 
    • 3 hrs
  • Anonymous 
    • £100 
    • 5 hrs
  • Anonymous 
    • £20 
    • 11 hrs
  • Ann Bywater 
    • £10 
    • 18 hrs
  • Rebecca Rachmany 
    • £180 
    • 20 hrs
See all

Organizer and beneficiary

Dr. Tess Lawrie, MBBCh, PhD 
Organizer
Bath, South West England, United Kingdom
The Evidence-based Medicine Consultancy Ltd 
Beneficiary
  • #1 fundraising platform

    More people start fundraisers on GoFundMe than on any other platform. Learn more

  • GoFundMe Guarantee

    In the rare case something isn’t right, we will work with you to determine if misuse occurred. Learn more

  • Expert advice, 24/7

    Contact us with your questions and we’ll answer, day or night. Learn more